crs3123
Small moleculeexperimental
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2012 (NCT01551004)
Timeline
Indications
Mechanism of action
- Methionyl-tRNA synthetaseINHIBITOR
metG inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- crs3123
- crs3123
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06988423 | Phase 1 | May 9, 2025 | Crestone, Inc, National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT04781387 | Phase 2 | Jan 5, 2021 | Crestone, Inc, National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT02106338 | Phase 1 | Jun 1, 2014 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT01551004 | Phase 1 | May 1, 2012 | National Institute of Allergy and Infectious Diseases (NIAID) |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 4 | 2 | 2 | 2012 |
| Crestone, Inc | For profit | 2 | 2 | 2 | 2021 |
2 organizations
Page 1 / 1